What is TB-500?
TB-500 is a name used for a peptide fragment related to thymosin beta-4. The FDA substance record identifies an N-terminally acetylated fragment with the sequence LKKTETQ. That definition is narrower than the way the name sometimes appears in commercial discussions. A listing that uses TB-500 as a synonym for the entire thymosin beta-4 molecule leaves a fundamental identity question unanswered.
The fragment and the parent peptide
Full-length thymosin beta-4 contains 43 amino acids. The seven-residue fragment is not simply a smaller package of the same evidence. Sequence length, terminal chemistry and the surrounding molecular structure can matter to a biological experiment. The useful comparison therefore starts with the exact substance in the methods section, rather than with a product title or a shared reference to tissue repair.
What the regulatory sources actually establish
The FDA substance record supports a defined identity. A 2026 advisory-committee briefing separately reviews the nominated fragment and the available evidence. These documents serve different purposes: a substance identifier establishes what a name refers to, while a committee review examines a regulatory question. Neither an identifier nor the existence of a committee discussion should be presented as a marketing authorization.
How to assess a claim about tissue research
For a claim based on thymosin beta-4, ask whether the source tested the full-length molecule, the acetylated fragment, an unmodified fragment or another preparation. Then separate a cell-migration measurement from tissue repair in an animal, and both from a meaningful outcome in people. If the molecule changes between the source and the claim, mark that transfer of evidence explicitly rather than silently treating it as direct support.
Identity, purity and sample quality
A short label is insufficient to establish what a vial contains. Sequence documentation, terminal modifications, analytical identity and an appropriate content assay answer different questions. An apparently clean chromatogram does not by itself prove sequence, sterility or suitability for a procedure. A laboratory record should tie each analytical result to the specific lot and method, not merely attach a generic certificate to the compound name.
What remains unresolved for a reader
This dossier does not establish a therapeutic benefit, a preparation procedure or a personal-use amount. The central unresolved issue in many summaries is whether their cited experiment studied this exact fragment at all. When that cannot be confirmed, the responsible conclusion is uncertainty about applicability, not a positive or negative claim about every possible use.
